Renaming and Rebranding a Groundbreaking Treatment

 

 

Pharmability originated from a pivotal scientific discovery made at the Karolinska Institutet, where Professor Anna-Lena Spetz uncovered the unique immunomodulatory potential of a single-stranded oligonucleotide, now known as TIR-01. The result? A groundbreaking treatment of atopic dermatitis. The name and identity? Knowledgeable, innovative and with a feeling of relief.

The color palate is humanistic and optimistic. At the same time, it’s comforting, indicating therapies that relive itching symtoms and redness. Pharmability stays cool.

“Our new identity encapsulates everything we are, with effectiveness and credibility. It’s a foundation for communication that has already proven scaleable.”

 

Leo Holmgren, Pharmability

Related work

This could be the beginning of a beautiful friendship

We love new encounters, by chance or by appointment.
Let’s talk.

Contact us